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Summary 
Moloney Murine Leukemia Virus (MoMuLV) causes T cell neoplasms in rodents but is not known 
to be a pathogen in primates.  The core protein and enzyme genes of the MoMuLV genome 
together with an amphotropic envelope gene are utilized to engineer the cell lines that generate 
retroviral vectors for use in current human gene therapy applications. We developed a producer 
done that generates a very high concentration ofretroviral vector particles to optimize conditions 
for gene insertion into pluripotent hematopoietic stem ceils. This producer cell line also generates 
a much lower concentration of replication-competent virus that arose through recombination. 
Stem cells from rhesus monkeys were purified by immunoselection  with an anti-CD34 antibody, 
incubated in vitro for 80-86 h in the presence of retroviral vector particles with accompanying 
replication-competent virus and used to reconstitute recipients whose bone marrow had been 
ablated by total body irradiation.  The retroviral vector genome was detected in circulating ceUs 
of five of eight transplant recipients of CD34 + cells and in the circulating cells of two recipients 
of infected, unfractionated bone marrow mononudear cells. Three recipients of CD34 + cells 
had a productive infection with replication-competent virus. Six or seven mo after transplantation, 
each of these animals developed a rapidly progressive T  cell neoplasm  involving the thymus, 
lymph nodes, liver, spleen, and bone marrow.  Lymphoma cells contained 10-50 copies of the 
replication-competent virus, but lacked the retroviral vector genome. We conclude that replication- 
competent viruses arising from producer ceUs making retroviral vectors can be pathogenic in 
primates, which underscores the importance of carefully screening retroviral producer clones used 
in human trials  to exclude contamination with replication-competent  virus. 
R~ 
troviral vectors have the capacity to transfer genes with 
high effidency into a broad spectrum of target cells 
(1-4). Such vectors have considerable flexibility with respect 
to the nature of the transferred genetic information. Gener- 
ally, use of appropriate  regulatory and/or ILNA processing 
signals provides sufficient  gene expression  to achieve  the desired 
experimental or therapeutic goal. Indeed, the first human gene 
therapy protocols are based on the use of retroviral vectors (5). 
This work was previously published in abstract form only (1991. Blood. 
78:[suppl  1] 19a). 
Most retroviral vector systems use some components of 
the Moloney murine leukemia virus (MoMuLV)  1 (1-4). This 
virus induces T cell leukemia/lymphomas in rodents with 
long latency primarily by the mechanism of insertional muta- 
1Abbreviations used in  this paper: MCE  mink  cell  focus;  MoMuLV, 
Moloney murine leukemia virus; rglL-3, recombinant  gibbon interleukin 
3; rhG-CSF, recombinant  human granulocyte colony-stimulating  factor; 
rhGM-CSF, recombinant  human granulocyte/macrophage  colony-stimu- 
lating factor; rhSCF, recombinant  human stem cell factor; STLV, simian 
T cell leukemia virus; WBC, white blood cell. 
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tegrated provirus activate adjacent cellular genes leading to 
dysregulated cell proliferation and the development of neo- 
plasms. Viral replication in vivo is required for disease induc- 
tion. In mice infected with MoMuLV there is consistent emer- 
gence of xenotropic viruses by recombination of the MoMuLV 
genome  with  cellular  sequences (6,  7).  These  xenotropic 
viruses,  detected by their capacity to induce loci on mink 
cells, are called mink cell focus (MCF) viruses. There is evi- 
dence that the MCF envelope protein activates the IL.2 receptor 
(9)  and may play a role in oncogenesis when expressed in 
preneoplastic  thymus cells. 
The use of MoMuLV components for generation of ther- 
apeutic viral vectors, despite the known capacity of this virus 
to induce neoplasms in rodents, is based both on recombinant 
DNA engineering strategies  and in vivo safety studies.  Retro- 
viral vectors are produced in packaging cells (murine fibro- 
blasts) that contain two or more genetic components intro- 
duced by conventional gene transfer strategies (1,  10). The 
vector proviral genome contains both the coding sequences 
for the gene to be expressed in target cells and the LTRs and 
adjacent sequences that provide required packaging, replica- 
tion, insertion, transcriptional control, and KNA processing 
signals  (1-4). Packaging cell lines contain a second proviral 
genome designed to express the viral proteins necessary for 
infectious  virus  formation.  In  early  packaging  lines,  this 
"helper" genome was mutated to remove the genetic element 
necessary for packaging  of its own fuU-length KNA tran- 
script into virus particles (10).  Although useful for experi- 
mental purposes, such "first generation" packaging cell lines 
consistently  gave rise  to  replication-competent  viruses by 
recombination between the RNA transcript derived from the 
helper genome and that derived from the vector genome, and 
therefore could not be used for human gene therapy applica- 
tions (1-4).  Second generation packaging ceU lines contain 
a helper proviral genome into which additional  mutations 
had been introduced to reduce the probability of recombina- 
tion and thus replication-competent  virus production  (11). 
In third generation packaging lines, genetic components en- 
coding the ecotropic gag/pol and amphotropic envelope pro- 
teins were separated on different transcriptional units, thereby 
reducing the likelihood of generation of replication-competent 
virus by recombination (12-14). In addition to these changes 
in the helper genome, unnecessary sequences have been elim- 
inated from the vector genome and mutations introduced into 
that portion of the gag region retained to achieve high viral 
titers (1, 2).  These modifications in the vector genome re- 
duced the likelihood that replication-competent virus would 
emerge from producer clones currently used to generate vectors 
for use in human  studies  (14). 
Support for use of MoMuLV-based systems for generation 
of therapeutic gene transfer vectors was derived from safety 
studies in primates that suggested that murine amphotropic 
replication-competent virus was not pathogenic (4, 16, 17). 
large amounts of amphotropic virus, introduced by intrave- 
nous injection or by implantation of virus-producing autol- 
ogous fibroblasts, established only transient  infection in normal 
or immunosuppressed animals but failed to induce disease. 
Sera from rhesus monkeys rapidly reduced the titer of am- 
photropic virus by two orders of magnitude, and replication- 
competent virus could not be detected in the sera of infected 
animals  (16). 
Our work has focused on the use of retroviral vectors for 
gene transfer into hematopoietic stem cells. Although strate- 
gies have been developed for reasonably efficient gene transfer 
into murine repopulating stem cells (18, 19), retroviral medi- 
ated  gene  transfer  into  primate  stem  cells  has  been more 
difficult to achieve  (18-20).  We developed a retroviral pro- 
ducer  clone  that  generates  a  very  high  concentration  of 
retroviral  vector  particles  (109/ml)  allowing  a  high  mul- 
tiplicity of infection for the target stem cell population (21). 
This producer clone was derived by use of a vector genome 
and packaging cell lines known to give rise to replication- 
competent virus by recombination, and indeed our clone pro- 
duced  a  lower  level  of  replication-competent  virus 
(103-104/ml).  Because  murine  amphotropic  replication- 
competent viruses were thought to be nonpathogenic in pri- 
mates  (16,  17),  we utilized  this  producer  clone  as an  ex- 
perimental tool for optimizing conditions for gene transfer 
into primate hematopoietic stem cells. In the course of these 
experiments,  we observed that replication-competent  virus 
is capable of inducing an aggressive T  cell neoplasm in pri- 
mates analogous to the disease observed in rodent species (6-8). 
Materials  and Methods 
Bone Marrow Transplantation.  Young  adult  rhesus  macaques 
(Macaca mulatta) that were serologically negative for simian T cell 
leukemia virus (STLV), simian immunodeficiency virus, and simian 
retrovirus, and had blood type K were used in these studies. Animals 
were quarantined  and housed in accordance with the guidelines 
set by the Committee on Care and Use of Laboratory Animals of 
the Institute  of Laboratory Animal R~sources, National Research 
Council  (DHHS Public. No. NIH 85-23, revised 1985) and the 
policies set by the Veterinary Resource Program of the National 
Institutes  of Health.  Before the  transplantation  procedure,  in- 
dwelling central venous catheters were established by standard sur- 
gical techniques (22). 
Day 0 was designated as the day of the bone marrow cell reinfu- 
sion. 100 ml of antologous peripheral blood were collected on days 
-11 and  -10 and stored at 4~  After warming  to 37~  this 
peripheral blood was used for transfusion on day -4 at the time 
of bone marrow harvest. On day -9, 70 mg/kg of 5-Pluorouracil 
was administered as a single intravenous bolus (23) to all except 
two animals. These two received  recombinant human stem cell factor 
(rhSCF) (24) intravenously (200 #g/kg/day) for days -14 to -4. 
On day -4, ",qS0 ml of bone marrow containing 1-4  x  109 total 
cells was harvested surgically from the femurs, iliac crests, and ischial 
tuberosities into heparinized syringes under general anesthesia. On 
day  -2 and/or  -1, animals received total body ~/-irradiation to 
ablate the endogenous bone marrow (Table 1). Two animals were 
transplanted with the total mononuclear ceU fraction after 4 d of 
direct coculture with the retroviral producer cells (21). These animals 
received no 5-FU or SCF before bone marrow harvest. Standard 
supportive care for bone marrow transplant  recipients was initi- 
ated after the irradiation (22). Autologous or crossmatched whole 
blood transfusions were administered when the hematocrit was less 
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binant human granulocyte colony-stimulating factor (rhG-CSF) (25) 
at a dose of 5/~g/kg/day or recombinant human granulocyte/mac- 
rophage colony-stimulating factor (rhGM-CSF) (22,  26) was ad- 
ministered as a continuous intravenous infusion until the white 
blood cell (WBC) count reached 10,000/ram  s (Table 1). 
Immunoselection of CD34 + Cells.  Upon harvesting, the bone 
marrow was diluted with HBSS and passed through wire mesh 
(Baxter  Heahhcare  Corp.,  Deer  field,  IL)  to  remove  clumps. 
Mononuclear cells were isolated by density gradient centrifugation 
using Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ), and 
washed. Cells expressing CD34 were isolated by immunoselection 
as previously described (27,  28). 
To  estimate  the  progenitor  concentration,  bone  marrow 
mononuclear cells and CD34 ~ immunoselected cells were plated 
in methylcellulose in IMDM containing 30% FCS, 0.9% deionized 
BSA,  and  10 -4  M  2-ME  (Terry Fox  Laboratories,  Vancouver, 
Canada).  Unfractionated cells were plated at 5  x  104/ml, whereas 
the CD34 ~ cells were plated at 100 and 1,000  cells/ml, rhSCF 
(100 ng/ml) (24), rhGM-CSF (26) (10 ng/ml), and recombinant 
erythropoietin (29) (2 U/ml) were added to the culture medium. 
Colonies were scored 12-14 d after initiation of triplicate cultures. 
Retraviral Producer Cells.  The cell clone, N263A2 (21), was main- 
tained in DMEM (Biofluids Inc., Rockville, MD) with 15% FCS. 
Medium conditioned by amphotropic producer cells during the 
12-18 h of proliferation from semiconfluency to confluency con- 
tained  '~109  infectious  neo  R  vector  particles  and  103-104 
replication-competent virus particles per ml.  Fresh conditioned 
medium was used without freezing for all bone marrow cell in- 
fections. 
Culture of Bone Marrow Cells.  Immunoselected CD34 + cells 
were resuspended at 2  x  10Vml in DMEM plus 15% FCS sup- 
plemented with glutamine, penicillin, and streptomycin. One half 
of the total volume in which the cells were suspended was culture 
medium derived from the amphotropic producer cell line as de- 
scribed above. The amphotropic producer line had been engineered 
to secrete recombinant gibbon I1.-3 (rglL-3) and recombinant human 
IL-6 (rhlL-6) in low concentration (21). Polybrene (6/xg/ml), rhSCF 
(24) (100 ng/ml), and rhlL-6 (30) (50 ng/ml) were added. For cer- 
tain animals, rhlL-3 (31) was also added at 10 ng/ml. One half of 
the medium was changed every 24 h and replenished with medium 
containing fresh virus, growth factors, and polybrene. Cocuhure 
of unfractionated mononuclear cells of two animals (Table 1) with 
retroviral producer cells was  as previously described (21). 
In some cases (Table 1), CD34-selected cells were cocultured with 
a previously established autologous stromal layer. The stromal cells 
were obtained by aspirating bone marrow from the iliac crest into 
preservative-free  heparin  1-2  wk  before initiation  of the bone 
marrow transplantation protocol. This marrow was suspended  in 
HBSS and mononuclear cells were recovered by density gradient 
centrifugation. These cells were washed and suspended  at 2  x 
l&/ml in DMEM containing 15% FCS supplemented with anti- 
biotics.  Nonadherent cells were removed 48-72 h later.  The ad- 
herent cells were washed 2-3 times whh HBSS and fresh tissue 
culture medium was added. The adherent cells were passaged after 
trypsinization as necessary to allow continuous growth. 12-24 h 
before the main bone marrow harvest, when the adherent cells were 
30-50% confluent, nonadherent cells were removed and fresh cul- 
ture medium  added.  For cocuhure, CD34"  selected  cells were 
added (2  x  10S/ml) in culture medium containing fresh virus, 
polybrene, and growth factors and maintained as specified above. 
ImmunophenotyFing  of Tumor Cells.  Tumor samples were ana- 
lyzed both by flow cytometry and by immunohistology. For flow 
cytometric analysis, suspensions  of mononudear cells from periph- 
eral blood or tissues infiltrated with tumor were prepared by stan- 
dard techniques including density gradient centrifugation. The 
following antibodies were used to characterize these cells. FITC- 
conjugated anti-CD2, PE-conjugated anti-CD20, and their isotype- 
matched controls were obtained from Coulter Immunology (Hia- 
leah, FL); PE-conjugated anti-CD4 along with its isotype matched 
control were obtained from Becton Dickinson & Co. (Mountain 
View, CA); and FITC-conjugated anti-CD8 along with its isotype- 
matched control were obtained from Gen Trak, Inc.  (Plymouth 
Meeting, PA). The rat mAb, 83A25 (32, 33), was used in these 
studies  to recognize an epitope of the envelope  gp70 molecule 
common to the different classes of murine leukemia retroviruses. 
The rat IgG2a isotype control was obtained from Zymed (San Fran- 
cisco, CA). A PE-conjugated goat F(ab')2 anti-rat Ig (Tago Inc., 
Burlingame, CA) was used as the secondary antibody. Antibodies 
were used at the concentrations specified by the manufacturers or 
based on titration to achieve maximal staining intensity on ceils 
known to be antigen positive. 
For immunohistological studies, portions of involved tissues were 
embedded in OCT (Miles Laboratories,  Naperville, IL) and snap 
frozen in  2-methyl butane  mixed with  dry ice.  Air-dried  ace- 
tone-fixed frozen sections were stained using the avidin-biotin com- 
plex immunoperoxidase procedure as previously described (34). The 
panel of mAbs used included Leu2a (CD8), Leu3a, (CD4), LeuSb 
(CD2), Leu12 (CD19), Leu16 (CD20), MY4 (CD14), (Becton Dick- 
inson & Co.), LCA (CD45) (Dako Corp., Carpinteria, CA) and 
Bfl (/3 chain of the TCR) (T Cell Sciences, Inc., Cambridge, MA). 
All of the above antibodies,  developed against  human hematopoi- 
eric cell surface antigens, crossreact  with the corresponding cell 
surface antigens in the rhesus monkey. 
DNA Analysis.  DNA was recovered from Peripheral blood cells 
and tumor tissues  by standard techniques (35).  The vector and 
replication-competent amphotropic proviral genomes were detected 
by PCR amplification using 400 ng of genomic DNA as a tem- 
plate with specific primers as previously described (21). The se- 
quence of the primers used to amplify sequences in the vector ge- 
nome or in the amphotropic or ecotropic envelope gene have been 
previously published (21) whereas those for the rhesus globin genes 
are given in the legend to Fig. 4. Conditions used for amplification 
PCR were as follows: amphotropic or ecotropic envelope gene or 
neo  R proviral sequences:  denaturation, 94~  for 1.5';  annealing, 
52~  for 2.5'; elongation, 72~  for 3.0' (25 cycles); and rhesus 
qr globin primers: denaturation, 94~C for 1'; annealing,  55~  for 
1'; and dongation, 72~  for 1' (25 cycles). Southern blot analysis 
was performed after restriction enzyme digestion using standard 
techniques (35). 
Detection of Replication-Competent Virus.  The S*/L- assay was 
performed on serum samples and media conditioned by suspended 
tumor cells using PG4 cells (36).  This assay detects replication- 
competent xenotropic or amphotropic retrovirus by mobilization 
of a focus forming proviral genome within the PG4 ceils. DNA 
samples were assayed for STLV-I using a sensitive PCR.-based assay 
(37). Samples of sera were analyzed for antibodies to the retroviral 
core protein, p30 (16), using a kit obtained from Victor Laborato- 
ries,  (Burlingame, CA). 
Results 
Bone Marrow Transplantation.  14 animals were the subjects 
of  these  studies;  eight  animals  were  transplanted  with 
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tions designed to introduce the retroviral vector; two animals 
received CD34 § cells without in vitro culture;  two irradi- 
ated animals received no cells; and two animals were trans- 
planted with total bone marrow mononuclear cells cocultured 
with  retroviral  producer cells  (Table  1). 
The immunoselection procedure was highly efficient re- 
sulting in an average recovery of 4.0% of the starting mono- 
nuclear cells with an average 27-fold enrichment of donogenic 
progenitors;  1.8-5.2%  (average 3.5%)  of the CD34 + cells 
gave rise to colonies in vitro. The CD34 § fraction contained 
90-100%  of the clonogenic progenitors.  There was an av- 
erage fourfold (range 2.0-7.6) increase in the number of cells 
during in vitro  incubation  of the  CD34  selected cells. 
The eight  animals  that  received CD34 selected cultured 
cells  recovered to a WBC  count of >1,000/ram 3 in 20  + 
Table  1.  Characteristics  and Outcome of Bone Marrow Transplantation 
Radiation  Culture  No.  of  Days to WBC  Clinical 
Animal  Pretreat  dose (Rads)  conditions~  cells infused  count of 1,000s  status 
CD34 Selected cells 
88053  5-FU  500  x  2  SCF,  IL-6  8.4  x  107  17  Lymphoma, died 
(Day 200) 
88049*  SCF  500  x  2  Stroma  2.2  ￿  10  s  20  Lymphoma, died 
SCF,  IL-6  (Day 182) 
15445  5-FU  500  x  2  Stroma  4.3  x  107  19  Lymphoma, died 
SCF,  IL-6, IL-3  (Day 206) 
15186  5-FU  500  x  2  SCF,  IL-6  1.0  x  10  s  20  Alive 
(Day 458) 
15326"  SCF  500  x  2  Stroma  2.8  x  10  s  23  Alive 
SCF,  IL-6  (Day 385) 
15222  5-FU  500  x  2  Stroma  1.8  x  10  s  24  Alive 
SCF,  IL-6  (Day 349) 
15365  5-FU  500  x  2  Stroma  4.3  x  107  16  Alive 
SCF,  IL-6  Day (329) 
15160  5-FU  500  x  2  Stroma  3.6  x  107  19  Alive 
SCF,  IL-6, IL-3  (Day 262) 
Unfractionated Mononuclear Cells 
95A  None  600  x  2 
1474  None  600  x  2 
Controls 
88054  5-FU  850 
88075  5-FU  1,000 
15520  5-FU  500  x  2 
16A  5-FU  500  x  2 
Viral  producer  5.0  x  10  s  25  Alive 
IL-3, IL-6  (Day 790) 
Viral  producer  7.1  x  10  s  23  Alive 
IL-3, IL-6  (Day 798) 
1.2  x  107 
3.0  x  107 
16  Alive 
(Day 282) 
14  Alive 
(Day 226) 
24  Sepsis,  died 
(Day 67) 
22  Sepsis, died 
(Day 58) 
* 5-FU, 5-Fluorouracil (70 mg/kg) given 5 d before the marrow harvest (Day 9). SCF, Stem cell factor (200 #g/kg) infused 
marrow harvest (Days -14 to  -4). 
SCF  =  Stem cell factor (100 ng/ml);  IL-6 =  (50 ng/ml);  IL-3 =  (10 ng/ml). 
S Animals 16A, 95A, and 1474 received GM-CSF starting on day 2 whereas the others received G-CSF starting on day 14. The 
sion was continued until the WBC count exceeded 10,000/ram  3. 
for the 10 d before 
growth factor infu- 
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1). The two animals that received CD34 + cells that had not 
been  cultured  in  vitro  reconstituted  to  a  WBC  count  of 
>1,000/ram 3  on  day  14  or  16.  Although  the  nontrans- 
planted controls reached a WBC count of 1,000 on day 22 
or 24 with growth factor support, engraftment was incom- 
plete and survival brief (Table 1). The two animals (95A and 
1474) that received unfractionated bone marrow mononuclear 
cells after cocuhure with retroviral producer cells also recon- 
stituted fully although 22 or 24 d were required to reach a 
WBC  of >l,000/mm 3. 
~ansfer of  the Vector  Genome into  Hematopoietic  Cells.  After 
reconstitution,  five of the eight experimental animals that 
received CD34 §  cells showed evidence of retroviral vector 
transfer into reconstituting hematopoietic cells. In four animals, 
the PCR signal with primers specific to the neo  P" gene gave 
a signal intensity indicating that 0.1-1.0% of the circulating 
cells contained the N2 proviral genome (Fig. 1 and data not 
shown). The N2 genome was detected in these animals' cir- 
culating cells immediately postreconstitution and persisted 
during the period of follow-up in all animals in which the 
viral genome was initially detected. The PCR signal derived 
from the N2 proviral genome in the circulating cells of one 
animal (15445) was of an intensity, compared to standards, 
that suggested that 10% of the cells contained the viral ge- 
home (Fig.  1). DNA from T  lymphocytes recovered by im- 
munoselection and from granulocytes recovered by density 
gradient centrifugation gave PCR signals of intensities sug- 
gesting that 10 and 5% of the circulating cells of these lineages, 
respectively, contained the vector provirus (data not shown). 
These cell fractions were >95% pure as determined by cyto- 
logical examination or FACS  |  analysis. The two animals trans- 
planted with unfractionated mononuclear cells had 0.2-1.0% 
retrovirally marked cells in both T  lymphocyte and granulo- 
cyte fractions for more than I yr posttranscription (data not 
shown). 
Detection of  Amphotropic Envelope Coding Sequences in Cir- 
culating Blood Cells.  Over a period of several  weeks, three 
of the animals in this study developed a rapidly progressive 
lymphoid neoplasm (see below), alerting us to the possibility 
that replication-competent virus may have been present in 
vivo. These animals had been clinically stable with full he- 
matopoietic reconstitution before developing this syndrome 
6-7 mo after transplantation  (Table 1).  Primers specific for 
the amphotropic envelope gene (21) were used in a PCR anal- 
ysis of peripheral blood cell DNA obtained at various intervals 
after transplantation  (Fig.  1).  In the first samples obtained 
(days 16-22), a weak signal was detected in all three animals 
suggesting that  1.0-10%  of the circulating cells contained 
the amphotropic envelope gene. However, by days 58-69 in 
all three animals, the signal detected was of an intensity equiva- 
lent to that observed with DNA from the amphotropic pack- 
aging cell line which suggests that virtually all of the cir- 
culating cells contained one or more copies of the amphotropic 
envelope gene. At this time, the WBC differential was un- 
remarkable in the three animals. The amphotropic envelope 
gene was present in DNA prepared from purified T lympho- 
cytes and granulocytes of animal no. 15445 (data not shown). 
7 of the 10 animals that reconstituted with bone marrow 
cells exposed to the amphotropic virus have remained free 
of neoplastic disease for periods of observation ranging from 
6-24 mo (Table 1). The wild-type amphotropic envelope gene 
was detected in DNA from peripheral blood leukocytes of 
six of these animals with a signal intensity suggesting that 
0.1-0.5%  of the circulating cells contained the coding se- 
quences. In one animal (15365), a subsequent DNA sample 
from peripheral blood cells was negative for the amphotropic 
envelope gene sequences. 
Detection of Replication-Competent Virus In  Viva  Plasma 
from two  of the three tumor-bearing  animals  (88049  and 
15445)  was  obtained  at  the  time  of  death  for  assay  for 
replication-competent virus. Infectious viral particles in titers 
of 104 or 10  s, respectively, was detected using serial dilutions 
of sera in the S+L -  assay (Table 2). In contrast, sera obtained 
5-24  mo after transplantation  from the seven animals that 
failed to develop a tumor did not contain detectable replication- 
competent virus as determined in this assay. Serum was assayed 
for antibodies reactive with the MoMuLV core protein, p30, 
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Figure 1.  Detection of the vector and am- 
photropic  envelope  sequences  in  circulating 
blood cells from three transplant recipients. (A) 
Primers specific  for the vector genome (19) were 
used  on  template DNA prepared  from  cir- 
culating blood cells at various  intervals  after 
transplantation.  The positive control was a 1 
to 100 dilution (/~g//~g) of DNA from a pro- 
ducer line known to contain  one copy of the 
vector genome with DNA from circulating cells 
of a  control monkey.  The  DNA from  this 
monkey also served as the negative control. (B) 
Primers specific for the amphotropic envelope 
sequences (21) were used with the same set of 
DNA samples as template. In this case, the posi- 
tive DNA, used undiluted,  was derived from 
the pA317 packaging cell line that contains 3-5 
copies of the helper genome. The negative con- 
trol DNA was derived from circulating  cells 
of a nontransplanted  recipient  monkey. Table  2.  Replication-Competent Virus in Transplant Recipients 
Estimated maximal percent of PBLs 
containing coding sequences* 
Serum Abs 
Animal  Vector  Amphotropic envelope  to viral p30 
Replication-competent 
virus in serum*  Clinical status 
% 
CD34  Selected cells 
88053  1  100  ND  ND 
99049  1  100  -  104/ml 
15445  10  100  -  10  s 
15186  0  0.5  +  <101 
15326  0  0.2  +  <(101 
15222  1.0  0.2  +  <(101 
15365  1.0  0  +  <(101 
15160  0  0.1  +  <(101 
Unfractionated  Mononuclear Cells 
95A  2  <(1  +  ND 
1474  0.5  ND  +  ND 
Lymphoma, died 
(Day 200) 
Lymphoma, died 
(Day 182) 
Lymphoma, died 
(Day 206) 
Alive 
(Day 458) 
Alive 
(Day 385) 
Alive 
(Day 349) 
Alive 
(Day 329) 
Alive 
(Day 262) 
Alive 
(Day 790) 
Alive 
(Day 790) 
* These estimates are based on signal intensity  of the PCR product compared to appropriately diluted controls. 
* Detected in serial dilutions of serum by S+L -  assay. 
by Western blot methodology. Antibody was detected in the 
sera of the seven animals that remained free of disease, but 
was  not  detectable  in  the  two  animals  with  lymphoma 
(Table 2). 
Characteristics of the Lymphoid Neoplasm.  Two animals died 
182 and 200 d,  posttransplantation. At autopsy, each was 
found to have diffuse lymphadenopathy, a large thymic mass 
and hepatosplenomegaly.  Pleural and pericardial effusions were 
present.  One animal (88049)  had severe pulmonary atelec- 
tails due to pleural effusions, whereas the other (88053) died 
of a spontaneous splenic rupture. A third animal (15445) ex- 
hibited a progressive increase in WBC count over a period 
of 6 wk to more than 60,000/mm  3,  most of which were 
lymphoblasts (Fig. 2 A) accompanied by progressive  anemia 
(Hb  =  5.9 gm/dl) and thrombocytopenia (28,000/mm3). A 
chest x ray revealed an enlarged thymic shadow. The animal 
was euthanized on day 206 posttransplantation. Autopsy re- 
vealed pleural effusions and ascites, diffuse lymphadenopathy, 
thymic enlargement, hepatosplenomegaly,  and tumor nodules 
in the kidney and liver. Histopathological study of all involved 
organs in each animal revealed a diffuse, high grade lymphoid 
neoplasm consistent with lymphoblastic lymphoma (Fig. 2 
B). Immunophenotypic analysis of frozen sections prepared 
from both an enlarged lymph node and the thymic mass re- 
vealed a T  cell phenotype (data not shown) with positive 
staining for the T cell-associated antigens Bfl, CD2, and CD8, 
but not for CD4. There was no staining for the B cell-as- 
sociated  antigens CD19 and CD20,  nor was there staining 
for the myeloid associated antigen CD14. In addition, flow 
cytometric analysis of cell suspensions prepared from the lymph 
Figure 2.  Morphology  of the neoplastic  cells. (A) Peripheral blood from animal 15445, obtained 198 days  posttransplantation  and stained with the 
Wright-Giesma technique. (B) A section of thymus from animal 15445 stained with hematoxylin  and eosin. ￿ 
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munophenotypic results. The tumor cells were found to be 
CD2- (Fig. 3) and CDS-positive, but negative for the CD4 
antigen. 
Cytogenetic  analysis  was  performed  on  spontaneously 
dividing cells from pleural fluid. An isochromosome 8 resulting 
from fusion of the long arms at the centromeric region was 
present in 3 of 12 spreads analyzed, one spread was tetraploid, 
and four other spreads had abnormalities on chromosome 3 
or 4. 
Lympkoraa  Cells Contain and Express an Ampkotropic Proviral 
Genome and Produce  Replication-Competent Virus.  A PCR anal- 
ysis using primers specific for the amphotropic envelope gene, 
verified the presence  of its  coding sequences  in  all  tissues 
infiltrated with tumor cells from the three animals (Fig. 4). 
Ecotropic envelope sequences,  known to be present in the 
producer  line (21),  were not  detected in tumor cell DNA 
(data not shown). These same tissues were negative for the 
vector genome as reflected by analysis using primers specific 
for the neo  p" coding and adjacent envelope sequences  (Fig. 
4).  DNA samples from the tumor-infiltrated tissues of the 
three animals were also negative for STLV-type I sequences 
as shown by PCR analysis with STLV-I specific primers (data 
not  shown).  Primers  specific  for  globin  gene  sequences 
provided a control to verify that each DNA sample was capable 
of serving as an effective template for PCK. 
Southern blot analysis with a probe for envelope gene se- 
quences demonstrated a proviral genome in DNA  from all 
tissues examined with a copy number  ranging from  10  to 
more than 50 as estimated by densitometric analysis (Fig. 5). 
Insertion site analysis using an enzyme that yields a junction 
fragment demarcated by a site in the proviral genome and 
a second in adjacent DNA gave a complex pattern with differ- 
ences among the DNA samples from the three animals (Fig. 
5). In contrast, the proviral genome copy number was similar 
among DNA samples obtained from three different diffusely 
infiltrated tissues of the same animal, and insertion site anal- 
ysis gave a common pattern of bands for the three samples. 
￿9  1  1  10  100  lO00 
CD2-FITC 
Figure 3.  Expression  of the retroviral  envelope  protein on the surface 
of neoplastic CD2 positive cells. A single cell suspension was prepared 
from the thymus of animal 15445 at the time of killing. The antibodies 
and isotope  controls  used are described  in Materials  and Methods. Isotope 
control (  ......  ). Antienvelope  or CD2 antibody (  ). The two- 
dimensional bitmap gives the data obtained with the two specific anti- 
bodies and indicates  that more than 99% of calls were positive  with both 
antibodies. 
Figure 4.  Detection  of  the amphotropic  envelope  gene  sequences  in tumor 
cell DNA and the absence of the vector genome in tumor cells. (Lane 
I) D NA extracted  concurrently  from circulating  cells  of  a control monkey; 
(lanes 2 and 3) duplicate  DNA samples extracted  from spleen  cells of an- 
imal 88053; (lane 4) DNA extracted  concurrently from circulating  cells 
of  a control monkey;  lanes  4 and 5 duplicate  DNA samples  extracted  from 
the thymus of animal  88049; and (lanes 7 and 8) DNA from marrow and 
thymus,  respectively,  from animal  15445. (A) Analysis  with primers specific 
for the amphotropic envelope  gene sequences (21). The positive  control 
DNA (lanes 9 and 10) was extracted from pA317 cells whereas the nega- 
tive control DNA (lanes 11 and 12) was recovered  from mouse 3T3 cells. 
(B) Analysis  with primers specific  for the vector genome (21). The posi- 
tive  control  was DNA extracted  from the cell  line N763 known to contain 
one copy  of  the proviral  genome,  whereas  the negative  control  DNA (lanes 
1I and 12) was extracted  from circulating  cells ofa nontransplanted  recip- 
ient. (C) Analysis  with primers specific  for the rhesus "y-globin  gene se- 
quences: 5' primer = 5' GTTGC~AGTGAAGAAACTGC  3' and 3' primer 
= 5' TAGCCTCAGACTCTGTTTGG  3'. The set of DNA samples ana- 
lyzed were identical to those utilized in B. 
A  suspension of thymus cells from animal 15445  stained 
brightly and uniformly with an antibody specific for murine 
leukemia retroviral gp70 envelope protein (Fig. 3). These cells 
and the pleural fluid cells were cultured in vitro in RPMI 
containing  15%  FCS and  5  U/ml  of IL-1B  (Cetus  Corp., 
Berkeley, CA), 10 Units/ml of IL-2 (Genzyme Corp., Boston, 
MA) or a combination of both growth factors.  Cells from 
each  source continued to  divide for  ",~2 wk.  Conditioned 
medium harvested from each cell population  after 48  h  in 
vitro was found to contain replication-competent virus in the 
S+L -  assay on PG4  cells  at  a  titer  of "~104/ml. 
Discussion 
The apparent pathogenesis of the neoplastic process in these 
primates resembled that resulting from MoMuLV infection 
of rodent species (6-8).  Replication-competent virus infec- 
tion was apparently established during the in vitro infection 
of immunoselected CD34 § cells with subsequent amplifica- 
tion of virus within hematopoietic tissues. Expression of the 
amphotropic viral envelope protein was documented in neo- 
plastic cells and seems likely to have been present in preneo- 
plastic thymus cells as well. The genome of the monoclonal 
tumor cells was riddled with exogenous provirus providing 
multiple opportunities for insertional activation or inactiva- 
1132  Virus-induced  T Cell Lymphoma Figure 5.  Southern blot analysis of DNA extracted from tumor tissues 
of the three animals having lymphoma.  (A) (Lanes 1 and 4) DNA from 
spleen of animal 88053; (lanes 2 and 5) DNA from the thymus of animal 
88049; and (lanes 3 and 6) DNA from the thymus of animal 15445. Diges- 
tion was with PstI for the DNA in lanes I-3 and with Sstl in lanes 4-6. 
PstI cuts toward the 5' end of the amphotropic 4070 genome. This is the 
replication-competent  virus likely to arise by recombination in the pro- 
ducer cell line (11, 14). The probe fragment containing  envelope sequences 
detects a junction fragment  containing proviral and genomic DNA se- 
quences. SstI cuts in the LTRs of the predicted replication-competent viral 
genome and once internally  yielding  a 5.7-kb proviral fragment. (B) Anal- 
ysis of DNA from three tissues of animal 15445. (Lanes 1 and 5) bone 
marrow;  (lanes 2 and 6) thymus; and (lanes 3 and 7) lymph node. Lane 
4 contains DNA from circulating cells of a control rhesus monkey. Lanes 
I-7 were derived from a radioautograph  exposed for 8 h whereas lanes 
8 and 9 were derived from a radioautograph exposed for 48 h. Lane  8 con- 
tains the same DNA present in lane 7 whereas the DNA in lane 9 is de- 
rived from  the pA317 packaging cell line. The DNA in lanes 1-4 was 
digested with PstI, and that in lanes 5-9 with SstI. The probe used was 
a Clal fragment (4987-7645) from the envelope region of the helper ge- 
home (11). 
tion of genes involved in the regulation of cell growth and 
regulation. 
Establishment of a chronic replication-competent virus in- 
fection and the evolution of an aggressive neoplastic process 
was not predicted based on previous work in rhesus monkeys 
(4, 16, 17). However, there are at least two important differ- 
ences between our protocol and those employed in the prior 
safety testing of the amphotropic helper virus.  Total body 
irradiation in the doses we used to ablate bone marrow causes 
much more severe  immunosuppression than the combination 
of  prednisone and cyclosporin (38). Furthermore, the monkeys 
used in the prior safety studies had intact bone marrow and 
lymphoid function whereas the animals in our studies were 
recipients of autologous grafts from which the T  cells had 
been removed. T cell depletion from marrow grafts is known 
to delay restoration of T cell-dependent immune functions 
in  transplant  recipients  (39). We surmise  that  severe im- 
munosuppression  was important in disease pathogenesis. 
Early amplification of a replication-competent  viral infec- 
tion after engraftment distinguished  the three animals that 
developed lymphoma from the seven that did not, but no 
single experimental parameter can be implicated in the estab- 
lishment and evolution of this infection.  Neither the agent 
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used for pretreatment (5-FU or SCF) nor the exact condi- 
tions  of in vitro culture of the CD34 selected cells seemed 
relevant since these variables were different among the three 
animals in which neoplasms developed (Table 1). Rather, each 
of the seven animals that controlled the viral infection had 
detectable serum antibodies to a viral protein,  whereas two 
animals with lymphoma that were studied apparently failed 
to mount a humoral immune response to this  antigen. 
In mice infected with MoMuLV, recombination between 
an endogenous retroviral  genome and the MoMuLV leads 
to the emergence of a MCF virus that induces transformed 
loci of  mink cells in vitro (6-8). The mixtures of  replication- 
competent virus present in mice with lymphoma have a char- 
acteristic dual-tropic specificity.  The xenotropic envelope  pro- 
tein is thought to have a role in the early pathogenesis  of 
the neoplastic process, perhaps by heightening sensitivity of 
T cells to IL-2 (9). In contrast, MoMuLV-induced disease in 
rats is not accompanied by the emergence of a virus having 
unique host cell specificity.  MoMuLV appears to be sufficient 
to cause disease in this species (6). The situation in the rhesus 
monkeys with lymphoma has not yet been resolved. There 
are at least two potential  sources of a unique virus distinct 
from the replication-competent  amphotropic virus that was 
demonstrable in medium derived from the producer clone 
(21). Recombination between this replication-competent virus 
and another proviral genome in the murine fibroblasts in vitro 
could have  resulted in the emergence of a mixed population 
of virus from the producer clone. Conversely, productive in- 
fection  in  vivo  by  the  original  amphotropic replication- 
competent virus from the producer cell line could conceiv- 
ably have mobilized a primate endogenous proviral genome 
(40) by recombination. Either mechanism could have led to 
emergence of complement-resistant virus with enhanced sur- 
vival in rhesus plasma. Future studies will evaluate these pos- 
sibilities by characterization of the replication-competent virus 
recovered from these animals. 
In neoplasms induced by MoMuLV in rodents, several  genes 
may be activated by proviral insertion. These include the myc, 
N-myc, myb, Ha-ras, LcK, and Ets-1 genes and several other 
less well characterized loci, designated Mlvi 1-4 (4, 6,  8). 
Various combinations of two or more mutations are thought 
to be required for the emergence of a neoplastic process. In 
any specific  tumor, such a combination of  mutations is thought 
to arise sequentially leading to stepwise evolution of  the neo- 
plastic phenotype. The primate loci homologous to those 
characteristically disrupted in rodents by MoMuLV will be 
examined in future studies for evidence of proviral insertion. 
Our  work was  undertaken to  optimize conditions for 
retroviral mediated gene insertion into repopulating hema- 
topoietic  stem  cells. The  retroviral  vector  genome  was 
identified in circulating blood and/or bone marrow cells in 
seven animals from the time of  reconstitution and continued 
to be present in 0.1-10%  of circulating cells throughout the 
period of observation (Table 2). In contrast, the replication- 
competent virus infection was progressive with a gradual in- 
crease in the proviral genome copy number in circulating cells 
(Fig. 1). We infer that insertion of the vector and replication- 
competent viral genomes were independent events. Supporting this interpretation is the fact that the cells of one animal 
(15365), contained the vector but not the amphotropic enve- 
lope gene sequences (Table 2), and that the tumors contained 
the amphotropic envelope gene but not the vector genome 
(Fig.  4).  Nonetheless, the ability of replication-competent 
helper virus to establish  infection in these animals created 
the possibility for mobilization of the vector genome and 
its spread throughout hematopoietic tissues after bone marrow 
reconstitution. This concern is particularly relevant to the 
one animal in which about 10% of cells contained the vector 
genome (15445) since replication-competent virus appeared 
to have amplified very early after transplantation in this an- 
imal (Fig.  1). Therefore, we cannot unequivocally interpret 
our studies with respect  to the use of these conditions for 
facilitating gene insertion into repopulating stem cells. Re- 
cent work in the canine model has yielded data documenting 
retroviral mediated gene insertion into cells capable of giving 
rise to multiple lineages (41, 42). Indeed, recent studies sup- 
port coculture with autologous stroma to facilitate retroviral 
mediated gene transfer into primitive hematopoietic cells (43). 
Our observations underscore the importance of avoiding 
replication-competent virus contamination in all retroviral 
vectors used for human gene transfer studies.  Undoubtedly, 
the  normal immune system provides  a  potent barrier  to 
murine-type replication-competent viral infection, but many 
patients who are candidates for gene transfer protocols have 
various degrees of immune dysfunction due to intrinsic dis- 
ease or because  of having received  chemoradiotherapy. An 
intrinsic barrier  within the host to replication-competent 
virus-induced disease is not likely to be reliable in such pa- 
tients.  Fortunately, the modifications introduced into the 
helper and vector genomes in second and third generation 
packaging  lines  have  rendered  generation  of replication- 
competent virus by recombination statistically improbable 
and practically undetectable (1-4,  11-14). Assiduous monitor- 
ing  of clinical  grade  vector  preparations  for  replication- 
competent virus adds another margin of safety. We conclude 
that our observations should not detract from future use of 
retroviral vectors  for human gene therapy. 
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